Month: March 2026

Kaye Gooch, MSW
Director of Community Programs
Amyloidosis Research Consortium

Members of ARC Leadership and the 2025-26 Amyloidosis Fellowship Cohort

For many people living with amyloidosis, the journey to diagnosis can be long and overwhelming. Symptoms can be vague, overlap with other conditions and affect multiple organs. It’s not unusual for patients to see several physicians before finally getting a diagnosis. And even then, finding a doctor who has specialized knowledge about the disease can be difficult.

And that’s why training more experts is so important.

While the amyloidosis community continues to grow, there are simply not enough trained experts to meet the needs of patients. As awareness increases and diagnostic tools improve, more people are being identified with the disease. But access to specialized care is still challenging.

To meet this important need, the Amyloidosis Research Consortium (ARC) created the Clinical Fellowship Program. The fellowship, made possible through an independent educational grant from AstraZeneca and Ionis Pharmaceuticals, is funding seven fellows in our first year. Our goal is simple: to build a strong pipeline of physicians who will dedicate their careers to advancing care for people with amyloidosis.

What is the Clinical Fellowship?

The ARC Clinical Fellowship is a one-year training program at leading amyloidosis centers in the United States. Fellows receive focused education in diagnosing and treating amyloidosis, under the guidance of established mentors with deep expertise in amyloidosis diagnosis and treatment.

In this program, fellows learn how to recognize the early signs of amyloidosis, use advanced diagnostic tools and imaging techniques, and learn more about research that will contribute to the science shaping future therapies for the disease. These fellows also work closely with teams in cardiology, hematology, neurology and other disciplines to gain the broad perspective that amyloidosis care demands.

Why This Matters for Patients

Early diagnosis can significantly affect outcomes. The sooner amyloidosis is diagnosed the sooner treatment can begin. Fellows trained specifically in this disease are better equipped to spot red flags and shorten the diagnostic journey for future patients, leading to a better quality of life.

Just as importantly, these fellows become lifelong leaders in research and innovation. They contribute to clinical trials, develop new treatment strategies and work to improve standards of care, which benefits the broader amyloidosis community. For patients and families, the impact of this program is personal. Every newly trained specialist represents faster diagnoses, more informed treatment decisions, and greater hope.

Meet the 2025-26 ARC Clinical Fellows

The first class of ARC Fellows represents the future of amyloidosis care. These seven physicians bring a diverse set of experiences, passions and perspectives, united by a shared commitment to improving amyloidosis care.

• Dr. Antonio Berumen Martinez at Boston Medical Center & Boston University Chobanian & Avedisian School of Medicine
• Dr. Nelson Barrera at Columbia Irving Medical Center
• Dr. Saloni Srivastava at Mass General Brigham
• Dr. Nour Beydoun at Northwestern University
• Dr. Sadia Tanami at Oregon Health & Science University
• Dr. Ayesha Hasan at University of Chicago Hospitals and Endeavor Health System
• Dr. Artrish Jefferson at University of Texas Southwestern Medical Center

“The field of amyloidosis is both clinically challenging and at the forefront of medicine. There are still so many difficult questions that motivate me as an investigator to pursue answers so that we can ultimately help all our patients.”

— Dr. Antonio Berumen Martinez, ARC Clinical Fellow, Boston University Chobanian & Avedisian School of Medicine

Learn more at arci.org/fellowship.

Your support helps make this possible. Donate Today to fund ARC Clinical Fellowships and help make expert care available to more patients.

This activity is supported by an independent educational grant from AstraZeneca and Ionis Pharmaceuticals.

This content is original to the Amyloidosis Research Consortium (ARC). Excerpts may be quoted with attribution and a link to the original post. Full republication without prior permission is not permitted.